A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The purpose of this study is to determine the safety of and to select a treatment regimen of pomalidomide (CC-4047) either as single-agent or in combination with prednisone to study further in patients with myelofibrosis with myeloid metaplasia (MMM).

Condition or disease	Intervention/treatment	Phase
Myelofibrosis With Myeloid Metaplasia; Myeloid Metaplasia; Myelofibrosis	Drug: Pomalidomide; Drug: Prednisone; Drug: Placebo to pomalidomide; Drug: Placebo to prednisone	Phase 2

Detailed Description:

Participants received study treatment in the Double Blind Treatment Phase for up to 12 cycles (336 days; 12 cycles of 28 days each). Participants who completed the Double-Blind Treatment Phase were unblinded and, if receiving pomalidomide and determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, could have continued on their current dose of pomalidomide until disease progression. Participants receiving placebo were discontinued from the study.

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	88 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:	Treatment
Official Title:	A Phase 2, Prospective, Randomized, Multicenter, Double-blind, Active-control, Parallel-group Study to Determine the Safety of and to Select a Treatment Regimen of CC-4047 (Pomalidomide) Either as Single-agent or in Combination With Prednisone to Study Further in Subjects With Myelofibrosis With Myeloid Metaplasia
Study Start Date :	April 2007
Actual Primary Completion Date :	May 2009
Actual Study Completion Date :	December 2013

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: Prednisone; Participants received oral prednisone from Day 1-28 of each 28-day cycle for up to 3 cycles (84 days), 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day, and pomalidomide placebo tablets on Days 1-28 for up to 12 cycles in the Double-Blind Treatment Phase. After the completion of cycle 12 and upon unblinding, participants were discontinued from the study.	Drug: Prednisone; Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day. Drug: Placebo to pomalidomide; Matching pomalidomide placebo tablets
Experimental: Pomalidomide; Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and prednisone placebo tablets on Days 1-28 for the first 3 cycles in the Double-Blind Treatment Phase. After the completion of Cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal.	Drug: Pomalidomide; Other Names: CC-4047; Pomalyst Drug: Placebo to prednisone; Matching prednisone placebo tablets
Experimental: Pomalidomide 2 mg + Prednisone; Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase. After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal.	Drug: Pomalidomide; Other Names: CC-4047; Pomalyst Drug: Prednisone; Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.
Experimental: Pomalidomide 0.5 mg + Prednisone; Participants received 0.5 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase. After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 0.5 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal.	Drug: Pomalidomide; Other Names: CC-4047; Pomalyst Drug: Prednisone; Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Percentage of Participants With a Clinical Response Within the First 6 Cycles of Treatment [ Time Frame: Up to 168 days ]

   A clinical responder was defined as either:

   1. A baseline red blood cell (RBC)-transfusion-dependent participant with a ≥ 56 consecutive day RBC transfusion-free period after the first dose of study drug, or
   2. A baseline RBC-transfusion-independent participant with an increase in hemoglobin of 2.0 g/dL or more from baseline for ≥ 56 consecutive days in the absence of RBC transfusions, or
   3. A participant with either a ≥ 50% reduction in palpable splenomegaly of a spleen that was ≥ 10 cm at baseline or a spleen that was palpable at > 5 cm and became not palpable.

   Participants who discontinued the study early without achieving clinical response were counted as non-responders.

Secondary Outcome Measures :

1. Percentage of Participants With a Clinical Response Within the First 12 Cycles of Treatment [ Time Frame: Up to 336 days ]

   A clinical responder was defined as either:

   1. A baseline red blood cell (RBC)-transfusion-dependent participant with a ≥ 56 consecutive day RBC transfusion-free period after the first dose of study drug, or
   2. A baseline RBC-transfusion-independent participant with an increase in hemoglobin of 2.0 g/dL or more from baseline for ≥ 56 consecutive days in the absence of RBC transfusions, or
   3. A participant with either a ≥ 50% reduction in palpable splenomegaly of a spleen that was ≥ 10 cm at baseline or a spleen that was palpable at > 5 cm and became not palpable.

   Participants who discontinued the study early without achieving clinical response were counted as non-responders.

2. Time to the First Clinical Response [ Time Frame: Up to 168 days ]

   The time to the first clinical response achieved within 168 days after the first study drug dosing date was calculated for participants who achieved a clinical response as:

   Start date of the first clinical response - the first study drug date +1.

   A clinical responder was defined as either:

   1. A baseline red blood cell (RBC)-transfusion-dependent participant with a ≥ 56 consecutive day RBC transfusion-free period after the first dose of study drug, or
   2. A baseline RBC-transfusion-independent participant with an increase in hemoglobin of 2.0 g/dL or more from baseline for ≥ 56 consecutive days in the absence of RBC transfusions, or
   3. A participant with either a ≥ 50% reduction in palpable splenomegaly of a spleen that was ≥ 10 cm at baseline or a spleen that was palpable at > 5 cm and became not palpable.
3. Duration of First Clinical Response [ Time Frame: Up to 40 months ]

   For RBC-transfusion-dependent patients, duration of response was calculated as the last day of response - first day of response +1, where the last day of response was the date of the first RBC-transfusion administrated at or more than 56 days after the response started. For patients who did not receive a subsequent transfusion after the response started, the end date of response was censored at the day of last hemoglobin assessment.

   For RBC-transfusion-independent patients, the duration of response was calculated as the last day of response - first day of response +1, where the last day of response was the earlier of the date of a hemoglobin increase of < 2.0 g/dL and the date of a RBC transfusion at ≥ 56 days after the response started. For patients whose hemoglobin measurements were always ≥ 2.0 g/dL and never received a RBC transfusion after response started, the end date of the response was censored at the date of last hemoglobin measurement.

   Kaplan-Meier methodology was used.

4. Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Subscale and Total Scores [ Time Frame: Baseline and Cycle 6 (168 days). ]

   The FACT-An comprises the four subscales of the 27-item FACT-General Scale (FACT-G), Physical Well-being, Social/Family Well-being, Emotion Well-being, Functional Well-Being, and the Additional Concerns Anemia subscale. Questions are rated on a scale from 0 to 4, where higher scores indicate more impact on quality of life.

   • Physical Well-being consists of 7 questions, the subscale score ranges from 0-28;
   • Social/Family Well-being consists of 7 questions, the subscale score ranges from 0-28;
   • Emotion Well-being consists of 6 questions, the subscale score ranges from 0-24;
   • Functional Well-Being consists of 7 questions, the subscale score ranges from 0-28;
   • Anemia subscale consists of 20 questions, the subscale score ranges from 0-80;
   • Total FACT-An score ranges from 0-188.
5. Change From Baseline in Hemoglobin Concentration for Responders [ Time Frame: Baseline, Cycle 6 (168 days) ]
   Change from Baseline in hemoglobin for participants with a clinical response within the first 6 cycles of treatment.
6. Change From Baseline in Hemoglobin Concentration for Non-Responders [ Time Frame: Baseline, Cycle 6 (168 days) ]
   Change from Baseline in hemoglobin for participants without a clinical response within the first 6 cycles of treatment.
7. Change From Baseline in Likert Abdominal Pain Scale [ Time Frame: Baseline and Cycle 6 (168 days) ]
   Participants rated abdominal discomfort or pain over the previous week on a scale from zero to ten, where zero is no discomfort or pain and ten is the worst pain imaginable.
8. Percentage of Participants With Clinical Response by Baseline JAK2 Assessment [ Time Frame: Up to 336 days ]
   Percentage of participants who achieved a clinical response, presented by participants with positive and negative janus kinase 2 (JAK2) V617F mutation results at Baseline.
9. Number of Participants With Adverse Events (AEs) [ Time Frame: From date of the first dose of the study drug until discontinuation or the data cut-off date (up to approximately 45 months). ]

   A serious AE (SAE) was defined as any AE which resulted in death or was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or constituted an important medical event (events that may have jeopardized the patient or required intervention to prevent one of the outcomes listed above).

   The severity of AEs were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 3.0) or according to the following scale:

   Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening; Grade 5 = Death.

   The Investigator determined the relationship between study drug and the occurrence of an AE as "Not Related" or "Related" (since the study was double-blinded, a patient receiving only prednisone could have an AE that was judged as related to pomalidomide, and vice-versa).

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Must sign an informed consent form
• Must be >18 years of age
• Must be diagnosed with myelofibrosis
• Eligibility is based on local pathology review of bone marrow aspirate and biopsy
• Screening total hemoglobin level < 10g/dL or transfusion-dependent anemia defined as per International Working Group (IWG) criteria.

• Must have adequate organ function as demonstrated by the following ≤ 14 days prior to starting study drug:

  • Alanine aminotransferase (ALT; SGPT)/aspartate aminotransferase (AST; SGOT) ≤ 3 x upper limit of normal (ULN), [unless upon judgment of the treating physician, it is believed to be due to extra-medullary hematopoiesis (EMH)].
  • Total Bilirubin <3x ULN or Direct Bilirubin <2 x ULN
  • Serum creatinine ≤ 2.0 mg/dL
  • Absolute neutrophil count ≥ 1,000/μL (≥ 1 x 10^9/L).
  • Platelet count ≥ 50,000 /μL (≥ 50 x 10^9/L).
• Patients must be willing to receive transfusion of blood products
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2 at screening.
• Must be able to adhere to the study visit schedule and other protocol requirements.
• No active malignancies with the exception of controlled prostate cancer, basal cell or squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.
• Must agree to follow pregnancy precautions as required per the protocol

Exclusion Criteria:

• Known positive status for human immunodeficiency virus (HIV), hepatitis B carrier, or active hepatitis C infection.
• Previous untoward reaction to corticosteroid (specifically, prednisone) therapy that was severe enough, in the opinion of the treating physician, to preclude study participation.
• The use of any growth factors, cytotoxic chemotherapeutic agents (e.g. hydroxyurea and anagrelide), corticosteroids, or experimental drug or therapy within a minimum of 28 days of starting CC-4047 and/or lack of recovery from all toxicity from previous therapy to grade 1 or better (e.g. alpha interferon may require 84 days of longer or washout).
• Prior therapy with CC-4047 or, lenalidomide or thalidomide for Myelofibrosis with myeloid metaplasia (MMM). (Prior prednisone use as a therapy for MMM is allowed, but not within 28 days of starting CC-4047).
• History of deep vein thrombosis or pulmonary embolism within one year of starting study medication.
• Any serious medical condition or psychiatric illness that would prevent, (as judged by the treating physician) the subject from signing the informed consent form or any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
• Pregnant or lactating females

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, California
UCLA School of Medicine Hematology/Oncology
Los Angeles, California, United States, 90095
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021-6007
New York Presbyterian HospitalWeill Medical College of Cornell University
New York, New York, United States, 10021
United States, Texas
MD Anderson Cancer Center Leukemia Department
Houston, Texas, United States, 77030
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109-4417
Austria
Medical University of Vienna, Department of Internal Medicine, Hematology
Vienna, Austria, A-1090
Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy, 27100
IRCCS Policlinico S. Matteo
Pavia, Italy, 27100
Spain
Hematology DepartmentHospital Clinic
Barcelona, Spain, 08036
United Kingdom
Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Trust
Sheffield, United Kingdom, S10 2JF

Sponsors and Collaborators

Celgene Corporation

Investigators

Study Director:	Robert Peter Gale, MD, PhD	Celgene Corporation

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Celgene Corporation
ClinicalTrials.gov Identifier:	NCT00463385 History of Changes
Other Study ID Numbers:	CC-4047-MMM-001
First Posted:	April 20, 2007
Results First Posted:	October 28, 2013
Last Update Posted:	July 3, 2015
Last Verified:	June 2015

Keywords provided by Celgene ( Celgene Corporation ):

Celgene; CC-4047; Myelofibrosis; myelofibrosis with myeloid metaplasia; myeloid metaplasia; JAK2; CC-4047-MMM-001; Prednisone; Phase II	pomalidomide; bone marrow histology; imids; MMM; Ashkenazi Jewish Population; exposure to Thorotrast; exposure to solvents (benzene and toluene); acute megakaryocytic leukemia; history of polycythemia vera

Additional relevant MeSH terms:

Primary Myelofibrosis; Metaplasia; Myeloproliferative Disorders; Bone Marrow Diseases; Hematologic Diseases; Pathologic Processes; Prednisone; Pomalidomide; Thalidomide; Anti-Inflammatory Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists	Physiological Effects of Drugs; Antineoplastic Agents, Hormonal; Antineoplastic Agents; Immunologic Factors; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Immunosuppressive Agents; Leprostatic Agents; Anti-Bacterial Agents; Anti-Infective Agents